HPV Vaccine Research
“Michael Smith Foundation for Health Research”
The funder does not disclose this information
Maximum Eligible Amount
Private Grant
Fund Type
The human papillomavirus (HPV) vaccine is highly effective at conferring protection against HPV and associated cervical cancers. Current practice calls for the vaccine to be administered in three doses; however, a reduced dosing regimen could save money and decrease the burden on patients.
- To determine if a two-dose HPV vaccine provide equivalent protection, MSFHR is funding a long-term national study. The Quadrivalent HPV Vaccine Evaluation Study (QUEST) will follow more than 8,500 teenage girls recruited from BC, Alberta, Quebec, and the Maritimes, for up to 10 years. The study will assess risk factors, prevalence, and the level of protection provided by a two-dose vaccine compared to three doses.
Log in with Google